News - Pricing

Filter

Current filters:

Pricing

Popular Filters

50 to 74 of 677 results

NZ’s PHARMAC tender reveals vibrant market for pharmaceuticals

NZ’s PHARMAC tender reveals vibrant market for pharmaceuticals

12-02-2014

The number of companies bidding to be suppliers through PHARMAC, New Zealand’s Pharmaceutical Management…

Asia-PacificGenericsHealthcarePricing

2014 to be transition year for Japan pharma

2014 to be transition year for Japan pharma

11-02-2014

2014 will be marked as a transition year for the Japanese Pharma industry – but the year is bound to…

Asia-PacificPharmaceuticalPricingRegulationResearch

EFPIA and EGA unite to propose a way forward in Romania

10-02-2014

The European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Generic…

Eastern EuropeHealthcareMarkets & MarketingPharmaceuticalPricing

Gilead to offer hep C drug sofosbuvir at greatly-reduced price in developing countries

Gilead to offer hep C drug sofosbuvir at greatly-reduced price in developing countries

07-02-2014

US biotech Gilead Sciences has indicated it would charge $2,000 per 24 week treatment course for the…

Anti-viralsBiotechnologyGilead SciencesGlobalIndiaPricingsofosbuvirSovaldi

Spain continues reduction of pharma spending and starts adopting value based pricing

04-02-2014

The Spanish Ministry of Health last week announced pharmaceutical spending data, which showed a new drop…

EuropeFinancialGenericsHealthcarePharmaceuticalPricingSpain

Pharma multinationals facing more pricing problems in India

Pharma multinationals facing more pricing problems in India

03-02-2014

Even as a battle royal appears to be brewing between India's drug price regulator, the National Pharma…

Asia-PacificAstraZenecaFinancialGlaxoSmithKlineIndiaNovartisPfizerPharmaceuticalPricing

Call for Medicaid formularies to block Gilead’s $1,000 per pill hepatitis drug

Call for Medicaid formularies to block Gilead’s $1,000 per pill hepatitis drug

30-01-2014

In a series of letters to be sent to state Medicaid directors starting this week, Michael Weinstein,…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPricingSovaldiUSA

Latest guidance from UK’s NICE on Xtandi disappoints Astellas

Latest guidance from UK’s NICE on Xtandi disappoints Astellas

28-01-2014

UK drugs watchdog the National Institute of Health and Care Excellence (NICE) has issued new draft guidance…

Astellas PharmaEuropeOncologyPharmaceuticalPricingRegulationUKXtandi

Pharma appeals to Ukraine Health Ministry on insulin supply problems

Pharma appeals to Ukraine Health Ministry on insulin supply problems

27-01-2014

The Association of Pharmaceutical Research and Development and the American Chamber of Commerce in Ukraine…

DiabetesEastern EuropeHealthcarePharmaceuticalPricingUkraine

UK’s NICE gives green light to Roche’s MabThera for GPA and MPA

UK’s NICE gives green light to Roche’s MabThera for GPA and MPA

24-01-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) today approved the use…

EuropeImmunologicalsMabTheraPharmaceuticalPricingRegulationRocheUK

NICE recommends Sanofi’s Aubagio as new treatment option for MS

NICE recommends Sanofi’s Aubagio as new treatment option for MS

22-01-2014

In final guidance, UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has…

AubagioBiotechnologyGenzymeNeurologicalNorthern EuropePricingRegulationSanofiUK

Gilead’s Sovaldi gains EC approval for chronic hepatitis C

Gilead’s Sovaldi gains EC approval for chronic hepatitis C

20-01-2014

US antivirals specialist Gilead Sciences has received marketing authorization from the European Commission…

Anti-viralsBiotechnologyEuropeGilead SciencesPricingRegulationSovaldi

ThromboGenics’ Jetrea gets positive reimbursement opinion in France

ThromboGenics’ Jetrea gets positive reimbursement opinion in France

17-01-2014

Belgian biotech firm ThromboGenics says that the Transparency Commission of the French National Health…

AlconBiotechnologyJetreaNovartisOphthalmicsPricingThromboGenics

Hint of minor added benefit for Bayer’s Stivarga seen by IQWiG

Hint of minor added benefit for Bayer’s Stivarga seen by IQWiG

13-01-2014

There was a hint of positive news for German drug major Bayer, when the German Institute for Quality…

BayerGermanyNorthern EuropeOncologyPharmaceuticalPricingRegulationStivarga

Trade group KEFEA claims picture on medicine prices distorted

13-01-2014

Constant references to “expensive” medicines and wrongful comparisons between the private sector…

EuropePharmaceuticalPricing

Report: India’s strong commercial opportunities hampered by bureaucracy and poor policy planning

Report: India’s strong commercial opportunities hampered by bureaucracy and poor policy planning

09-01-2014

Due to its large population and substantial unmet medical needs, India represents a market with strong…

Asia-PacificIndiaMarkets & MarketingPharmaceuticalPricingRegulation

Added benefit of Sanofi’s Aubagio not proven, says IQWiG

Added benefit of Sanofi’s Aubagio not proven, says IQWiG

08-01-2014

In yet another negative opinion from the German Institute for Quality and Efficiency in Health Care (IQWiG)…

AubagioGermanyNeurologicalNorthern EuropePharmaceuticalPricingRegulationSanofi

Added benefit of Bayer’s Eylea again not proven, says IQWiG

Added benefit of Bayer’s Eylea again not proven, says IQWiG

08-01-2014

For the third time in one year, the German Institute for Quality and Efficiency in Health Care (IQWiG)…

BayerEyleaGermanyNorthern EuropeOphthalmicsPharmaceuticalPricingRegulation

IQWiG says added benefit of GSK’s Tafinlar not proven

IQWiG says added benefit of GSK’s Tafinlar not proven

07-01-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

GermanyGlaxoSmithKlineNorthern EuropeOncologyPharmaceuticalPricingRegulationTafinlar

Medicines Australia welcomes greater input into PBS advisory committee

Medicines Australia welcomes greater input into PBS advisory committee

07-01-2014

Trade body Medicines Australia has welcomed the extended 10 week publication time for the agenda for…

AustraliaPharmaceuticalPoliticsPricing

German pharma price reform sees rebate reduction

German pharma price reform sees rebate reduction

02-01-2014

The new German coalition government has decided to partially revoke the AMNOG (Act on the Reform of the…

GermanyNorthern EuropePharmaceuticalPricingRegulation

UK’s NICE says yes to Cell Thera’s non-Hodgkin’s lymphoma drug Pixuvri

UK’s NICE says yes to Cell Thera’s non-Hodgkin’s lymphoma drug Pixuvri

31-12-2013

US biotech firm Cell Therapeutics’ Pixuvri (pixantrone), a treatment for an aggressive type of cancer…

BiotechnologyCell TherapeuticsEuropeOncologyPixuvriPricingRegulation

UK’s NICE backs second indication for Bayer’s Eylea

UK’s NICE backs second indication for Bayer’s Eylea

31-12-2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has today announced that…

BayerEuropeEyleaOphthalmicsPharmaceuticalPricingRegeneronRegulation

UK NICE draft guidance recommends Ferring’s Firmagon for prostate cancer

UK NICE draft guidance recommends Ferring’s Firmagon for prostate cancer

27-12-2013

UK drugs watchdog the National Institute for Health and Care Excellence has issued new draft guidance…

EuropeFerring PharmaceuticalsFirmagonOncologyPharmaceuticalPricingRegulationUK

50 to 74 of 677 results

Back to top